Genitourinary Cancer News

The FDA cleared an investigational new drug application for FT536, a chimeric antigen receptor natural killer cell therapy designed to treat adults with certain relapsed or refractory solid tumors.

The FDA lifted its clinical hold on a series of trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

The concept of patients continuing to exercise while undergoing active cancer treatment is not new, but it may need reinforcing.

Cutaneous adverse events appeared largely reversible and rarely led to therapy discontinuation among patients with metastatic melanoma treated with combination checkpoint inhibitors, according to a study in Cancer.

National Comprehensive Cancer Network has issued updated guidance on COVID-19 vaccination and pre-exposure prophylaxis for patients with cancer.

Patients with cancer who resided in low-income and rural areas appeared at higher risk for suicide than those in high-income and urban areas, according to a retrospective, population-based study in JAMA Network Open.

Sequential radiotherapy to defer systemic therapy appeared to be a feasible strategy with encouraging PFS and OS among select patients with oligometastatic renal cell carcinoma, according to a study published in The Lancet Oncology.

Cabozantinib demonstrated intracranial activity and appeared safe among patients with renal cell carcinoma and brain metastases, according to a study in JAMA Oncology.

The FDA cleared an investigational new drug application for P-MUC1C-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with locally advanced or metastatic epithelial-derived solid tumors.

A committee of experts from science, medicine and academia, among other fields, has recommended NASA proceed with a proposal for a universal, career-long radiation dose limit for all astronauts.